Clinical Trials
19 trialsNCT03030378 2026-05-19
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01468896 2026-04-29
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02483312 2025-12-01
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
University Health Network, Toronto
Phase 1 Active not recruiting
NCT00019188 2024-03-04
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT04388033 2020-06-09
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT01457131 2019-01-08
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02960594 2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1 Completed
NCT00622401 2017-11-14
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00004070 2017-04-20
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00003210 2015-04-15
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
National Cancer Institute (NCI)
Phase 2 Completed
NCT00015977 2014-03-07
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
University of Chicago
Phase 2 Completed
NCT00026182 2013-08-26
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026143 2013-06-05
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00028535 2013-06-04
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00054405 2013-04-09
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00004074 2013-02-28
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005604 2013-02-01
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00016289 2013-01-23
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00052377 2013-01-16
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
National Cancer Institute (NCI)
Phase 1/2 Terminated